enGene Holdings Inc.

About enGene Holdings Inc.

enGene is a company focused on advancing genetic medicine through a novel gene delivery platform. They specialize in locally administered, non-viral gene therapies targeting underserved diseases, particularly those affecting mucosal tissues. Their mission is to overcome limitations of viral-based gene therapies and bring gene therapy into mainstream clinical practice.

Products & Services

Detalimogene Voraplasmid:A non-viral gene therapy in development for non-muscle invasive bladder cancer (NMIBC), aimed at addressing significant patient burden and high clinical needs with a promising efficacy and safety profile, and ease of administration by urologists.

DDX(r) Platform:A breakthrough Dually Derivatized Oligochitosan (DDX) platform for genetic medicines, designed to transform mucosal cells into therapeutic production 'factories' for proteins and RNAs, providing local therapeutic effects while avoiding systemic immunogenicity associated with viral-based therapies.

Specialties

Non-viral gene therapy Mucosal tissue targeting Genetic medicine delivery platforms Treatment of underserved diseases Non-muscle invasive bladder cancer (NMIBC)

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 125000000 MR: - FA: US$125 million FAN: 125000000	D: 2026-01-20 FD: 2026-01-20	1 investors
2	RT: Public Offering T: - FT: Public Offering	A: 130000000 MR: - FA: 130 million FAN: 130000000	D: 2025-11-13 FD: 2025-11-13	6 investors
3	RT: Private Placement T: - FT: Private Placement	A: 60000000 MR: - FA: $60 million FAN: 60000000	D: 2024-10-25 FD: 2024-10-25	7 investors
4	RT: Private Placement T: - FT: Private Placement	A: 200000000 MR: - FA: 200 million FAN: 200000000	D: 2024-02-14 FD: 2024-02-14	17 investors
5	RT: Debt T: - FT: Debt	A: 50000000 MR: - FA: $50 million FAN: 50000000	D: 2023-12-22 FD: 2023-12-22	1 investors

Debt Latest

2026-01-20

$125.0M

1 investor (Pro only)

Public Offering 2025-11-13

$130.0M

Private Placement 2024-10-25

$60.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Matthew Boyd

Chief Regulatory Officer

J

Jill Buck

Chief Development Officer

A

Anthony T. Cheung

Co-Founder and Chief Scientific Officer

J

Joan Connolly

Chief Technology Officer

R

Ron Cooper

Chief Executive Officer

R

Ryan Daws

Chief Financial Officer and Head of Business Development

View 16 more team members with Pro

Unlock Full Team Directory

Recent News